- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07444866
Gestion Assistée par Apprentissage Automatique des Symptômes Comportementaux et Psychologiques de la Démence : Intervention pour les Aidants de Personnes Atteintes de Démence
Développement et test d'une intervention d'apprentissage automatique pour la gestion des symptômes comportementaux et psychologiques de la démence à l'intention des aidants de personnes atteintes de démence : une étude de conception expérimentale hybride
Develop and test a machine learning enabled management of behavioural and psychological symptoms of dementia intervention for dementia caregivers.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Hong Kong, Hong Kong
- The Education University of Hong Kong
-
Contact:
- Kee Lee Chou, PhD
- Numéro de téléphone: +85229487473
- E-mail: klchou@eduhk.hk
-
Contact:
- Vivien Tang, MSc
- E-mail: s1135125@s.eduhk.hk
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- aged 18 above
- family caregiver of an individual with a confirmed medical diagnosis of any type of dementia who has been residing in the community
- having been providing care for ADLs and IADLs for at least 20 hours per week for at least one year prior to recruitment
- have a smartphone
- have mild to moderate stress (the 14-item Chinese version Perceived Stress Scale).
Exclusion Criteria:
- having participated in any structured mind-body intervention, cognitive therapy, or structured psychosocial intervention in the 6 months prior to recruitment
- having acute psychiatric and medical comorbidities that are potentially life-threatening (e.g. suicidal ideation) or that limit the caregivers' participation or adherence (e.g. acute psychosis)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation factorielle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Active control
Active control |
No APP based coaching, no human coaching, no rerandomization, no MRT |
|
Expérimental: App & Human Coaching + Continue Intervention
First-line of coaching: App + Human Coaching Responder |
Continue with existing intervention plan |
|
Expérimental: App & Human Coaching + Increase intensity in human coaching
First-line of coaching: App + Human Coaching Non-Responder |
Increase intensity of human coaching |
|
Expérimental: App & Human Coaching + Booster
First-line of coaching: App + Human Coaching Non-Responder |
Add a booster session |
|
Expérimental: App Coaching + Continue Intervention
First-line of coaching: App Coaching Responder |
Continue with existing intervention plan |
|
Expérimental: App Coaching + Increase intensity in human coaching
First-line of coaching: App Coaching Non-Responder |
Increase intensity of human coaching |
|
Expérimental: App Coaching + Booster
First-line of coaching: App Coaching Non-Responder |
Add a booster session |
|
Expérimental: Human Coaching + Continue Intervention
First-line of coaching: Human Coaching Responder |
Continue with existing intervention plan |
|
Expérimental: Human Coaching + Increase intensity in human coaching
First-line of coaching: Human Coaching Non-Responder |
Increase intensity of human coaching |
|
Expérimental: Human Coaching + Booster
First-line of coaching: Human Coaching Non-Responder |
Add a booster session |
|
Expérimental: No Coaching + Continue Intervention
First-line of coaching: No Coaching Responder |
Continue with existing intervention plan |
|
Expérimental: No Coaching + Increase intensity in human coaching
First-line of coaching: No Coaching Non-Responder |
Increase intensity of human coaching |
|
Expérimental: No Coaching + Booster
First-line of coaching: No Coaching Non-Responder |
Add a booster session |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Stress
Délai: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
10-item Perceived Stress Scale; each item will be rated from 0=Never to 4=Very often. Total scores range from 0 to 40. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Depression
Délai: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Patient Health Questionnaire-9; Each item will be rated from 0=Not at all to 3=nearly everyday. Total scores range from 0 to 27 |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Sleep Quality
Délai: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Pittsburgh Sleep Quality Index; each item will be rated from 0=No difficulty to 3=Severe difficulty. Total scores range from 0 to 21. Higher scores indicating poorer sleep quality |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Anxiety
Délai: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Generalised Anxiety Disorder; each item will be rated from 0=not at all to 3=nearly every day. Total score range from 0 to 21. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Physical Health
Délai: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Lawton Instrumental Activities of Daily Living; each item will be rated 0=dependent to 1=independent. Total scores range from 0 to 8. |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Physical Health
Délai: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Activities of Daily Living; each item will be rate from 0=dependent to 5/10=independent. Total scores range from 0 to 100. |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Physical Symptoms
Délai: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Wahler Physical Symptoms Inventory; each item will be rated from 0=almost never agree to 5=agree almost every day. Total score range from 0 to 210. |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Chronic Illness
Délai: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Participants will indicate any presence of chronic illness (e.g., diabetes, asthma, high blood pressure). |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Caregiver Burden
Délai: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
12-item Zarit Burden Interview Scale ; each item will be rated from 0=Never to 4=Nearly always. Total scores range from 0 to 48. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Psychological Well-Being
Délai: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
18-item Ryff Psychological Well-Being scale, each item range from 1-strongly agree to 7-strongly disagree. Total score range from 18-126. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Physical and Mental Health
Délai: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
5-level EQ-5D version (EQ-5D-5L) will be utilized; the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflects |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Neuropsychiatric
Délai: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Neuropsychiatric Inventory Questionnaire; classified each of the 12 domain into presence of symptom, frequency, severity, and caregiver distress. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Memory and Behaviour Problems
Délai: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Revised Memory and Behavior Problems Checklist; a 24-item checklist from 0=never occurred/not at all to 4=daily/extremely. Higher score indicate more frequent behavioral problems/caregiver distress |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Caregiving
Délai: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Revised Scale for Caregiving Self-efficacy; 15-item scale. Total score is 100. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Kee Lee Chou, PhD, The Education University of Hong Kong
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 2023-2024-0387
- 22231921 (Autre subvention/numéro de financement: Research Fund Secretariat, Health Bureau)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .